Crossject signs ZEPIZURE® commercialization agreement for northern Europe
22 Dicembre 2023 - 7:30AM
Crossject signs ZEPIZURE® commercialization agreement for northern
Europe
Crossject to receive up to €1 million on
marketing approvals, plus a markup on sales linked to gross
margin
Agreement, with undisclosed strategic partner,
allows Crossject to benefit from strong expertise in the field and
provides impetus to commercial launches
Dijon, France 22 December, 2023, 07:30 CET -- Crossject
(ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company
developing needle-free auto-injectors for emergency
situations, announces it has concluded a commercialization
agreement in northern Europe for its innovative rescue therapy for
epileptic seizures ZEPIZURE®, previously known as ZENEO® Midazolam,
covering Germany, the UK, Denmark, Sweden, Finland and Norway.
Under the terms of the agreement, with an undisclosed strategic
partner, Crossject will receive milestone payments of up to €1
million in total, upon marketing authorizations granted in the
territories. Crossject will sell ZEPIZURE® with a markup that is a
share of the gross margin (net sales minus cost of goods).
Crossject covers regulatory development costs and owns potential
marketing authorizations, while Crossject’s partner controls and is
responsible for all commercial costs.
“We are pleased with this commercial agreement in European
territories, allowing us to benefit from strong expertise in the
field and providing significant impetus to our commercial launches
as we approach filing for regulatory approval,” said
Patrick Alexandre, CEO of Crossject. “This agreement
further progresses development of ZEPIZURE® and adds further to our
commercial prospects, as we have a firm order in place in the U.S.,
with the Biomedical Advanced Research and Development Authority,
and a commercialization agreement for Australia and New
Zealand.”
About Crossject
Crossject SA (Euronext: ALCJ;
www.crossject.com) is an emerging specialty pharma company. It is
in advanced regulatory development for ZEPIZURE®, an epileptic
rescue therapy previously known as ZENEO® Midazolam, for which it
was awarded a $60 million contract with the U.S. Biomedical
Advanced Research and Development Authority (BARDA). ZEPIZURE® is
based on the Company’s award-winning needle-free autoinjector
ZENEO®, designed to enable patients and untrained caregivers to
easily and instantly deliver emergency medication via intramuscular
injection on bare skin or even through clothing. The Company’s
other products in development include rescue therapies for allergic
shocks, adrenal insufficiencies, opioid overdose and asthma
attacks.
For further information, please contact:
Investors Natasha DrapeauCohesion Bureau+41 76 823
75 27natasha.drapeau@cohesionbureau.com |
MediaSophie BaumontCohesion Bureau+33 6 27 74 74
49sophie.baumont@cohesionbureau.com |
|
- Crossject_Press release_Europe_Commercialization_EN
Grafico Azioni Crossject (EU:ALCJ)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Crossject (EU:ALCJ)
Storico
Da Giu 2023 a Giu 2024